Skip Navigation

Text From Here.

Masaji Tani, M.D., Ph.D

  • Part-time lecturer
  • Clinic day:
  • Area of practice: Liver, biliary duct and pancreas, endocrine surgery
  • My speciality is the treatment of the patients with disease at pancreas, a biliary tract, liver and thyroid disease.  I would like to propose the optimal treatment by individualization.


  • 1987  graduated from Wakayama Medical University, School of Medicine


Professional Affiliation and Board Certification

Professional Affiliation

Member, The Japanese Society of Surgery

Member, The Japanese Society of Gastroenterological Surgery

Member, The Japanese Society of Hepato-Biliary-Pancreatic Surgery

Member, The Japanese Society of Pancreas

Member, The Japanese Society of Clinical Oncology

Member, The Japanese Society of Cancer Research

Member, The Japanese Society of Gastroenterology

Member, The Japanese Society of Gastrointestinal Endoscopy

Member, The Japanese Society for Endoscopic Surgery

Member, The Japanese Society of Biotherapy

Member, The Japan Biliary Association

Member, The Japanese Society of Thyroid Surgery

Board Certification

Japanese Board of Surgery

Japanese Board of Gastroenterological Surgery

Japanese Board of Gastrointestinal Endoscopy

Japanese Board of Hepato-Biliary-Pancreatic Surgery

Japanese Board of Cancer Therapy


Pancreatic Surgery

It is difficult to diagnose the pancreatic disease, because pancreas is “silent” organ. However, small tumor is increasingly found by progress in diagnostic modalities, such as CT.  In the 2nd surgery of Wakayama Medical University, we make a diagnose correctly by multimodalities, and we perform the optimal operation.  Moreover, the method of excision and the method of anastomosis are examined every day so that the quality of a long-term life may not be barred after an operation.

Clinical Study in Pancreatic Surgery

Although the resection of the pancreas is becoming safe, it still has complications and mortality.  Clinical trial is solved the problems scientifically to be safer and gentle to the body. Moreover, a pancreatic cancer is the representation of an intractable malignant tumor, and is promoting the clinical trial for the improvement in treatment results.

【Previous Prospective Study】
  1. The reconstruction method of pylorus-preserving pancreaticoduodenectomy: RCT (antecolica vs. retrocolica). 
  2. Early removal of the drain to prevent the infectious complications.
  3. Decreasing intraoperative bleeding for the early ligation of feeding arteries used by  preoperative 3-D CT imaging. 
  4. Pancreatic stent tube and postoperative complications. 
  5. RCT; (pylorus-preserving pancreaticoduodenectomy vs. pylorus-resecting pancreaticoduodenectomy)
  6. The phase I clinical trial by combined gemcitabine and VGEFR-2 peptide. 
【Prospective Study on going】
  1. Reconstruction of pancreaticoduodenectomy
  2. Vaccine therapy for pancreatic cancer (P-II/III)
【Basic Research】
  1. Pancreatic Cancer of Peptide Vaccine Treatment to Pancreatic Cancer,
  2. Gene-Analysis for pancreatic cancer
  3. Epithelium-mesenchymal transition
  4. The relationship between invasion and glycoprotein in pancreatic cancer
  5. Prediction of malignant factor for IPMN

The operation of endocrine surgery

In the 2nd surgery of Wakayama Medical University, we also perform operation of the patients with endocrine diseases represented by the thyroid gland and the adrenal gland.  There are a lot of diseases; cancer, a benign tumor, inflammation, hyper-function.